

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : James BEASLEY et al.
Serial No. : 09/538,038 Group Art Unit: To be assigned
Filed : March 29, 2000 Examiner: To be assigned
For : INSULIN AND IGF-1 RECEPTOR AGONISTS AND ANTAGONISTS

Commissioner of Patents
Washington, D.C. 20231
BOX: SEQUENCE

AMENDMENT TO COMPLY WITH 37 C.F.R. §§1.821-825

Sir:

This Amendment and Response is being filed in to comply with the requirements for applications containing nucleotide and/or amino acid sequence disclosures as instructed by the Notice to File Missing Parts dated May 25, 2000 for the above-identified patent application. The Amendment accompanies a Sequence Listing being submitted herewith in both written and computer readable forms, and a Statement under 37 C.F.R. 1.821(f) indicating that the written and computer readable forms of the Sequence Listing are identical. Also filed herewith is a Petition for an Extension of Time (two months) pursuant to 37 C.F.R. §1.136(a), and the fee pursuant to 37 C.F.R. §1.17(a)(2) to extend the time for response until September 25, 2000. Applicants respectfully request entry and consideration of the Sequence Listing, Amendment, and remarks herein at the time of examination of the application.

IN THE SPECIFICATION

Please amend the application as follows:

Page 10, line 1, after "sequence", second instance, insert --(SEQ ID NO: 2413)--;
line 3, before "wherein" insert --(SEQ ID NO: 2414)--;
line 9, after "sequences" insert --(SEQ ID NO: 2415)--;
line 12, after "Surprisingly" insert --(SEQ ID NO: 2415)--.